Lessons From Clinical Trial Setbacks Lead to Next Phase of Oncologic Advances

Source: Targeted Oncology, October 2020

It was certainly inevitable. In the wake of the enthusiasm around cancer immunotherapy trial results—with several positive trials presented annually at each American Society of Clinical Oncology (ASCO) meeting in more and more diseases over several years—setbacks have served as a grim reminder that our work isn’t finished.

Recently, the mood has changed to realism and, in some cases, pessimism, as some large trials reported as negative despite high expectations for efficacy.

Although earlier efforts in the targeted therapies field had known limited success, the various cancers, immunotherapy, and cancer vaccine field had lived through sine waves of excitement and failure.

READ THE ORIGINAL FULL ARTICLE